rs10318: Colorectal Cancer Recurrence and Genetic Associations
The rs10318 variant is a single nucleotide polymorphism located on chromosome 15. Research has identified a statistical association between this variant and the risk of cancer recurrence in patients diagnosed with stage II colorectal cancer.
What each genotype means
Baseline risk profile
This genotype represents the most common form of this variant observed in many populations. Research has investigated this variant's role in colorectal cancer susceptibility and recurrence, though findings across different studies have been inconsistent. You should discuss any concerns regarding colorectal health or cancer screening with your healthcare provider.
This is the most frequently observed genotype in many global populations.
Potential recurrence association
Some research has identified an association between this variant and the risk of cancer recurrence specifically in patients diagnosed with stage II colorectal cancer. Because study results have been inconsistent and the evidence is considered moderate, this information should be used only in consultation with your oncologist or medical team. Please discuss your specific clinical history and risk factors with your doctor.
This heterozygous genotype is found at varying frequencies depending on ancestral background.
Potential recurrence association
Some research has identified an association between this variant and the risk of cancer recurrence specifically in patients diagnosed with stage II colorectal cancer. Because study results have been inconsistent and the evidence is considered moderate, this information should be used only in consultation with your oncologist or medical team. Please discuss your specific clinical history and risk factors with your doctor.
This genotype is less common than the C/C genotype in most studied populations.
Understanding the rs10318 Variant
The rs10318 variant is a single nucleotide polymorphism (SNP), which is a common type of genetic variation where a single "letter" in the DNA sequence differs between individuals. This specific SNP is located on chromosome 15 at position 32,733,778. It is situated within the genomic region associated with the GREM1 gene. In genetics, SNPs are often used as markers to help researchers identify regions of the genome that may influence health outcomes or disease susceptibility. While rs10318 is a well-documented marker in genetic databases, it is important to understand that the presence of a specific allele at this location does not cause disease on its own. Instead, it represents a variation that has been statistically linked to specific clinical observations in research studies involving colorectal cancer patients.
The Role of the GREM1 Region
The rs10318 variant is located in proximity to the GREM1 gene. The GREM1 gene encodes a protein known as Gremlin 1, which plays a significant role in regulating cell signaling pathways, particularly those involved in development and tissue maintenance. Changes in the expression or function of genes in this region can influence how cells grow and divide. In the context of cancer research, scientists investigate these regions to determine if genetic variations might alter the biological environment of the colon or rectum. While the association between rs10318 and clinical outcomes is documented, the exact biological mechanism by which this specific SNP might influence cancer recurrence remains a subject of ongoing scientific inquiry. It is one of many genetic factors that researchers study to better understand the complex landscape of colorectal cancer progression.
Research and Clinical Associations
The primary evidence linking rs10318 to health outcomes comes from genome-wide association studies (GWAS) and subsequent clinical research. One notable study examined 26 SNPs in patients with stage II and III colorectal cancer who were receiving fluorouracil-based adjuvant chemotherapy. The researchers found that rs10318 was significantly associated with the risk of cancer recurrence specifically in patients with stage II disease. It is important to note that this evidence is considered moderate. The study highlights that while this variant shows a statistical correlation with recurrence, it is only one piece of a much larger puzzle. Other genetic markers were found to be associated with different outcomes in stage III patients, illustrating that genetic influences on cancer prognosis can vary significantly depending on the stage of the disease and the specific clinical context.
Population Frequency
The rs10318 variant is a common genetic marker. According to data from the 1000 Genomes Project and other genomic databases, the Global Minor Allele Frequency (GMAF) is approximately 0.2351. This indicates that the variant is present at a significant frequency across diverse human populations. Because it is a common variant, it is found in a large number of individuals who do not have colorectal cancer, reinforcing the fact that the presence of this SNP is not a diagnostic tool for the disease itself. Genetic frequency can vary by ancestry, and researchers continue to study these patterns to ensure that findings are applicable across different groups. Understanding the prevalence of such variants helps scientists distinguish between common genetic diversity and variations that may contribute to specific health risks.
Interpreting Genetic Information
Information regarding genetic variants like rs10318 is intended for educational purposes and should not be used for personal medical diagnosis or to make healthcare decisions. If you have concerns about colorectal cancer, your family history, or your personal health, it is essential to consult with a qualified healthcare professional or a genetic counselor. They can provide context based on your full medical history, lifestyle factors, and clinical screenings, which are far more predictive of health outcomes than any single genetic variant. You cannot change your genotype, but understanding your health risks through professional medical guidance allows for informed decisions regarding screenings and preventative care. Always discuss any questions about genetic testing or cancer risk with your clinician, as they are the only ones qualified to interpret these results in the context of your individual health.
How common is this variant?
The rs10318 variant is common, with a global minor allele frequency of approximately 0.2351 across diverse populations.
Frequently asked questions
Does having the rs10318 variant mean I will get colorectal cancer?
No. The rs10318 variant is a statistical marker associated with recurrence in patients who have already been diagnosed with stage II colorectal cancer. It is not a diagnostic test for the presence or development of cancer.
Should I get tested for rs10318?
There is no clinical recommendation for the general public to be tested for this specific variant. Genetic testing for cancer risk should only be performed under the guidance of a healthcare provider or genetic counselor.
What is the difference between a risk variant and a cause of cancer?
A risk variant is a genetic marker that shows a statistical correlation with a disease, whereas a cause is a direct biological factor that triggers the disease. Most common variants like rs10318 only slightly modify risk and are not direct causes.
How can I use this information to improve my health?
You should use this information to facilitate a conversation with your doctor about your personal and family health history. Focus on established preventative measures, such as regular screenings, which are the most effective way to manage colorectal cancer risk.
Sources & further reading
Educational information only, last refreshed 10/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10318?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in N/A
This variant is significantly associated with survival outcomes in patients with stage III colorectal cancer.
This variant is significantly associated with colorectal cancer recurrence in patients with stage III disease.
This variant is located in a low-complexity region and has been identified in recent genomic catalogs as a rare variant of interest.